In October 2009, Teva Pharmaceutical Industries filed a lawsuit against Mylan for infringement of multiple patents, with respect to patents on its glatiramer acetate drug–Copaxone. The patents cover pharmaceutical compositions containing it, methods of using it and processes for making it. Those patents expire in May 2014 and September 2015. No trial date is scheduled.
Teva brings another action against Mylan
Generics/News
|
Posted 03/12/2010
0
Post your comment
The latest action by Teva, brought in September 2010, concerns infringement of four patents related to the characterisation of Copaxone. The latest of these patents expires in February 2020.
Earlier in September 2010, Teva won a ruling in its battle to protect Copaxone. A court in the US denied a motion filed by Sandoz (the generics’ branch of Novartis) and Momenta Pharmaceuticals seeking to invalidate patents.
Copaxone multiple sclerosis treatment was developed by generics company Teva itself and is proving very lucrative. The ability for Teva to ward off generic competitors to Copaxone is one of the top concerns for investors in the Israel-based company.
Related article
FDA rejects second citizen petition for Teva’s glatiramer acetate drug
Source: Teva Press Release. Teva Files Complaint against Mylan for Infringement of Four Copaxone-Related Patents. 21 September 2010.
Research
Japan’s drug shortage crisis: challenges and policy solutions
Saudi FDA drug approvals and GMP inspections: trend analysis
Related content
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment